Abstract
The treatment of schizophrenia has paradoxically become increasingly complex with the greater availability and choice among antipsychotic medications. At the same time, there is still substantial unmet need, as confirmed by recent large pragmatic trials in schizophrenia, which provides the therapeutic context for antipsychotic polypharmacy. For patients and clinicians, then, the question of “why and when do I combine medications?” is now very challenging. All available evidence suggests that antipsychotic polypharmacy is common in clinical practice. Additionally, it is a topic of enduring interest among clinicians who are always eager to understand the information contributing to key therapeutic strategies. This chapter will provide a current appraisal of the extant evidence-base that informs the daily decision making process that is the clinician’s dilemma: how should I use antipsychotic polypharmacy to its best advantage in my practice? The chapter will also critically evaluate the extent to which polypharmacy truly impacts tolerability considerations in treating schizophrenia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AP:
-
Antipsychotic polypharmacy
- CATIE:
-
Clinical Antipsychotic Trials of Intervention Effectiveness
- EPS:
-
Extrapyramidal side effects
- FGA:
-
First generation antipsychotic
- NT:
-
Neurotransmitters
- PRN:
-
Pro re nata
- SGA:
-
Second general antipsychotic
References
Stahl SM (2012) Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand 125(5):349–351
Tamminga CA (2011) When is polypharmacy an advantage? Am J Psychiatry 168(7):663
Goff DC, Dixon L (2011) Antipsychotic polypharmacy: are two ever better than one? Am J Psychiatry 168(7):667–669
Stahl SM, Grady MM (2006) High-cost use of second-generation antipsychotics under California’s Medicaid program. Psychiatr Serv 57(1):127–129
Constantine RJ, Andel R, Tandon R (2010) Trends in adult antipsychotic polypharmacy: progress and challenges in Florida’s Medicaid program. Community Ment Health J 46(6):523–530
Baandrup L, Allerup P, Lublin H, Nordentoft M, Peacock L, Glenthoj B (2010) Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia outpatients. Acta Psychiatr Scand 122(5):367–374
Dussias P, Kalali AH, Citrome L (2010) Polypharmacy of schizophrenia. Psychiatry (Edgemont) 7(8):17–19
Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized clinical trials. Schizophr Bull 35(2):443–457
Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH (2011) Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168:702–708
Zink M, Englisch S, Meyer-Lindenberg A (2010) Polypharmacy in schizophrenia. Curr Opin Psychiatry 23(2):103–111
Lieberman JA, Stroup TS (2011) The NIMH-CATIE schizophrenia study: what did we learn? Am J Psychiatry 168(8):770–775
Bernardo M, Coma A, Ibañez C, Zara C, Bari JM, Serrano-Blanco A (2012) Antipsychotic polypharmacy in a regional health service: a population-based study. BMC Psychiatry 12(1):42
Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, Johnson JL, Barr AM (2010) Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71(5):566–573
Friedman JI, Lindenmayer JP, Alcantara F, Bowler S, Parak M, White L, Iskander A, Parrella M, Adler DN, Tsopelas ND, Tsai WY, Novakovic V, Harvey PD, Davis KL, Kaushik S (2011) Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology 36(6):1289–1295
Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assuncáo-Talbott S (2009) A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 70:1348–1357
Kantrowitz J, Javitt DC (2012) Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 25(2):96–102
Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshansky V, Kishimoto T, Kane JM (2011) Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res 131(1–3):58–62
Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A (1997) Sulpride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 171:569–573
Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD (2010) Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 35(5):1053–1062
Buckley PF, Stahl SM (2007) Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand 115(2):93–100
Fleischhacker WW, Heikkinen ME, Olié JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115–1125
Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC (2009) Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 29:165–169
Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case–control study. J Clin Psychiatry 71:103–108
Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69(5):476–483
Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009) Psychiatric comorbidities and schizophrenia. Schizophr Bull 35(2):393–402
Insel TR (2010) Psychiatrists’ relationships with pharmaceutical companies: part of the problem or part of the solution? JAMA 303(12):1192–1193
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Buckley, P.F. (2013). Antipsychotic Polypharmacy in Schizophrenia: ‘Secret Sauce or Wild Abandon?’. In: Ritsner, M. (eds) Polypharmacy in Psychiatry Practice, Volume II. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5799-8_1
Download citation
DOI: https://doi.org/10.1007/978-94-007-5799-8_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5798-1
Online ISBN: 978-94-007-5799-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)